SOD1 and amyotrophic lateral sclerosis: To assess the therapeutic effects of CTXD14SkM-EVs on mitigating inflammation-driven muscle atrophy in vivo, we utilized a well-established ALS mouse model expressing the human SOD1 protein with the pathogenic missense mutation G93A (SOD1G93A) [20].